Feasibility of Using a Bone-Targeted, Macromolecular Delivery System Coupled with Prostaglandin E1 to Promote Bone Formation in Aged, Estrogen-Deficient Rats
Authors:
- 29 August 2008
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (12) , 2889-2895
Abstract
Purpose Macromolecular delivery systems have therapeutic uses because of their ability to deliver and release drugs to specific tissues. The uptake and localization of HPMA copolymers using Asp8 as the bone-targeting moiety was determined in aged, ovariectomized (ovx) rats. PGE1 was attached via a cathepsin K-sensitive linkage to HPMA copolymer–Asp8 conjugate and was tested to determine if it could promote bone formation. Materials and Methods The uptake of FITC-labeled HPMA copolymer–Asp8 conjugate (P-Asp8-FITC) on bone surfaces was compared with the mineralization marker, tetracycline. Then a targeted PGE1-HPMA copolymer conjugate (P-Asp8-FITC-PGE1) was given as a single injection and its effects on bone formation were measured 4 weeks later. Results P-Asp8-FITC preferentially deposited on resorption surfaces, unlike tetracycline. A single injection of P-Asp8-FITC-PGE1 resulted in greater indices of bone formation in aged, ovx rats. Conclusions HPMA copolymers can be targeted to bone surfaces using Asp8, with preferential uptake on resorption surfaces. Additionally, PGE1 attached to the Asp8-targeted HPMA copolymers and given by a single injection resulted in greater bone formation measured 4 weeks later. This initial in vivo study suggests that macromolecular delivery systems targeted to bone may offer some therapeutic opportunities and advantages for the treatment of skeletal diseases.Keywords
This publication has 36 references indexed in Scilit:
- Osteotropic Peptide That Differentiates Functional Domains of the SkeletonBioconjugate Chemistry, 2007
- Pharmacokinetic and Biodistribution Studies of a Bone-Targeting Drug Delivery System Based onN-(2-Hydroxypropyl)methacrylamide CopolymersMolecular Pharmaceutics, 2006
- Human osteoblasts produce cathepsin KBone, 2006
- Water-soluble HPMA copolymer—prostaglandin E1conjugates containing a cathepsin K sensitive spacerJournal of Drug Targeting, 2006
- Skeletal function and structure: Implications for tissue-targeted therapeuticsAdvanced Drug Delivery Reviews, 2005
- Prostaglandin E-A Powerful Anabolic Agent for Generalized or Site-Specific Bone FormationCritical Reviews™ in Eukaryotic Gene Expression, 2003
- Prostaglandin E2 (PGE2) and Risedronate Was Superior to PGE2 Alone in Maintaining Newly Added Bone in the Cortical Bone Site After Withdrawal in Older Intact RatsJournal of Bone and Mineral Research, 1997
- Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human OsteoclastsJournal of Biological Chemistry, 1996
- Enantioselective Release of 5-Fluorouracil from N-(2-Hydroxypropyl)methacrylamide-Based Copolymers via Lysosomal EnzymesBioconjugate Chemistry, 1995
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987